BIOSIMILARS: MARKET ACCESS AND MARKET PENETRATION - A COMPARISON OF FRANCE AND GERMANY

被引：0
|
作者：
Freiberg, M. [1 ]
Schwarz, R. [1 ]
Khoury, C. [2 ]
机构：
[1] Quintiles Commercial Germany GmbH, Mannheim, Germany
[2] Quintiles Advisory Serv, St Ouen, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.553
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP16
引用
收藏
页码：A442 / A442
页数：1
相关论文
共 50 条
  • [1] MARKET ACCESS BARRIERS FOR BIOSIMILARS IN SPAIN AND GERMANY: EPOETIN ALFA EXAMPLE
    Hurtado, P.
    Vieta, A.
    Espinos, B.
    Badia, X.
    VALUE IN HEALTH, 2011, 14 (07) : A336 - A336
  • [2] COMPARISON OF MARKET ACCESS ROUTES OF DIGITAL HEALTH APPLICATIONS IN FRANCE, GERMANY AND THE UK
    Vollmer, L.
    Foxon, G.
    Danev, V
    Berard, I
    Benazet, F.
    Walzer, S.
    VALUE IN HEALTH, 2020, 23 : S579 - S579
  • [3] DEMAND AND SUPPLY SIDE REGULATION OF BIOSIMILAR MARKETS IN GERMANY, FRANCE AND ENGLAND AND ITS IMPLICATIONS FOR MARKET ACCESS OF BIOSIMILARS
    Walendzik, A.
    Altin, S.
    Wasem, J.
    VALUE IN HEALTH, 2017, 20 (09) : A656 - A657
  • [4] KEY DRIVERS FOR MARKET PENETRATION OF BIOSIMILARS IN EUROPE
    Remuzat, C.
    Dorey, J.
    Cristeau, O.
    Ionescu, D.
    Radiere, G.
    Mendoza, C.
    Toumi, M.
    VALUE IN HEALTH, 2016, 19 (07) : A497 - A497
  • [5] Exploitation of data available in open access on the consumption of medication in France: Use case on anti-TNF biosimilars market penetration
    Denis, Helene
    Lafon, Thomas
    Schmidt, Aurelie
    Vainchtock, Alexandre
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 167 - 168
  • [6] Biosimilars and market access: a question of comparability and costs?
    Simoens, Steven
    Verbeken, Gilbert
    Huys, Isabelle
    TARGETED ONCOLOGY, 2012, 7 (04) : 227 - 231
  • [7] Market access of biosimilars: not only a cost issue
    Simoens, S.
    Verbeken, G.
    Huys, I.
    ONCOLOGIE, 2011, 13 (05) : 218 - 221
  • [8] A health economic guide to market access of biosimilars
    Simoens, Steven
    Vulto, Arnold G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 9 - 17
  • [9] Biosimilars and market access: a question of comparability and costs?
    Steven Simoens
    Gilbert Verbeken
    Isabelle Huys
    Targeted Oncology, 2012, 7 : 227 - 231
  • [10] COPD DRUGS IN EUROPE - A COMPARISON OF MARKET ACCESS DECISIONS IN FRANCE, GERMANY, SWEDEN AND UK WITH THE PRISMACCESS DATABASE
    Vollmer, L.
    Walzer, S.
    Droeschel, D.
    de Paz, B.
    VALUE IN HEALTH, 2016, 19 (07) : A561 - A561
12345